Contineum Therapeutics reported cash and cash equivalents of $75.2 million as of September 30, 2026, compared to $75.6 million at the end of 2025. The company remains in the early stages of clinical development, heavily dependent on its lead candidate PIPE-791 and its collaboration with J&J for PIPE-307.
Contineum Therapeutics reported third-quarter 2026 financial results, highlighting a net loss of $18.7 million and a cash position of $244.5 million. The company noted that its current capital resources are sufficient to fund operations through mid-2029, providing runway past the estimated completion of its Phase 2 PROPEL-IPF clinical trial. Research and development expenses increased 45% year-over-year to $16.0 million, primarily driven by the PIPE-791 program.
“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients. We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”
Carmine Stengone, CEO, Contineum Therapeutics
“We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”